Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vector Science and TherapeuticsTSXV:PAIN -4.32%14 EBIT per Share is C$-0.30 as of Feb. 2026. GuruFocus rates TSXV:PAIN with a GF Score™ of 14/100. Among 685 Medical Devices & Instruments companies, Vector Science and Therapeutics ranks worse than 145985.26% on this metric.
Vector Science and Therapeutics's EBIT per Share for the
three
months ended in Feb. 2026 was C$-0.06.
Its EBIT per Share for the trailing twelve months (TTM) ended in Feb. 2026 was C$-0.30.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Vector Science and Therapeutics's EBIT per Share or its related term are showing as below:
TSXV:PAIN's 3-Year EBIT Growth Rate is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 9.6 * Ranked among companies with meaningful 3-Year EBIT Growth Rate only.
Vector Science and Therapeutics (TSXV:PAIN) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Vector Science and Therapeutics EBIT per Share Related Terms
Vector Science and Therapeutics EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vector Science and Therapeutics EBIT per Share Chart
EBIT per Share for the trailing twelve months (TTM) ended in Feb. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.30
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vector Science and Therapeutics (TSXV:PAIN) has a EBIT per Share of C$-0.30 as of Feb. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Vector Science and Therapeutics and its competitors. According to the industry distribution chart, Vector Science and Therapeutics ranks #999999 out of 685 companies in the Medical Devices & Instruments industry.
Is Vector Science and Therapeutics' EBIT per Share too high?
Vector Science and Therapeutics' current EBIT per Share is C$-0.30. Based on the distribution chart, Vector Science and Therapeutics ranks #999999 out of 685 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Vector Science and Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Vector Science and Therapeutics' EBIT per Share compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Vector Science and Therapeutics ranks #999999 out of 685 companies for EBIT per Share. This places Vector Science and Therapeutics in the lower half of its industry. The industry median EBIT per Share is 9.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Devices & Instruments company?
The median EBIT per Share among Medical Devices & Instruments companies is 9.60, based on 685 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Vector Science and Therapeutics and its competitors. For the Medical Devices & Instruments industry, the median EBIT per Share is 9.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vector Science and Therapeutics's current EBIT per Share is C$-0.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vector Science and Therapeutics stock overvalued right now?
Vector Science and Therapeutics (TSXV:PAIN) has a current EBIT per Share of C$-0.30. The current EBIT per Share is C$-0.30. Vector Science and Therapeutics' overall GF Score™ is 14/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Vector Science and Therapeutics (TSXV:PAIN), the current EBIT per Share is C$-0.30 as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vector Science and Therapeutics Business Description
Vector Science and Therapeutics Corp develops novel biomechanical devices and active transdermal drug and peptide delivery platforms to equip clinicians with non-systemic, localized interventions targeting a broad cross-section of diseases and conditions where systemic delivery of interventions compromises the therapeutic effect or introduces unacceptable harm.
14GF Score
Get the complete analysis for TSXV:PAIN
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:PAIN has been successfully added to your 
